Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619668 | 1.00 | EGFR (0.40) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL27294468 | 0.92 | EGFR (0.36) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL14141263 | 0.88 | GAA (0.37) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL30118004 | 0.87 | MAPT (0.33) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL30118003 | 0.87 | MAPT (0.33) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL13301891 | 0.86 | ALDH1A1 (0.42) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL26722401 | 0.86 | GAA (0.38) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL29444282 | 0.86 | MAPT (0.38) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL806906 | 0.86 | MAPT (0.38) | EGFRGAAALDH1A1MAPTKMT2A | |
| SCHEMBL30464047 | 0.84 | MAPT (0.37) | EGFRGAAALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023387-B2 | NIR-II emissive luminogens | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-02 | — | — | US | claimed |
| WO-2022199140-A1 | LIPID DROPLET TARGETED FLUORESCENT DYE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳先进技术研究院 | 2022-09-29 | — | — | WO | claimed |
| EP-1362579-B1 | Agent for dyeing keratinous fibres | HENKEL KGAA (DE) | 2006-05-24 | — | — | EP | claimed |
| EP-1300135-B1 | Agent for dyeing keratinous fibres comprising 2-aryliden-indolin-3-one derivatives | HENKEL KGAA (DE) | 2006-05-03 | — | — | EP | claimed |
| EP-1434552-A1 | METHOD FOR DYEING KERATINOUS FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-07-07 | — | — | EP | claimed |
| EP-1433785-A1 | Agents for the coloration of keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1362579-A1 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-11-19 | — | — | EP | claimed |
| EP-1002516-B1 | Hair dyes containing indan derivatives | WELLA AG (DE) | 2003-09-24 | — | — | EP | claimed |
| WO-2003030841-A1 | METHOD FOR DYEING KERATINOUS FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-17 | — | — | WO | claimed |
| EP-1300132-A2 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-04-09 | — | — | EP | claimed |
| EP-1300135-A1 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-04-09 | — | — | EP | claimed |
| US-6231622-B1 | MIXTURES; BLUE COLOR | WELLA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | claimed |
| EP-1002516-A1 | Hair dyes containing indan derivatives | Wella Aktiengesellschaft (DE) | 2000-05-24 | — | — | EP | claimed |
| US-5194463-A | LIGHT-ABSORBING POLYURETHANE COMPOSITIONS AND THERMOPLASTIC POLYMERS COLORED THEREWITH | EASTMAN KODAK COMPANY (US) | 1993-03-16 | — | — | US | claimed |
| JP-1009968-A | — | — | None | — | — | JP | disclosed |
| US-12622966-B2 | Compound for photothermal cancer therapy, composition including the same, and method for photothermal cancer therapy | PUKYONG NATIONAL INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2026-05-12 | — | — | US | disclosed |
| US-20250293254-A1 | SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2025-09-18 | — | — | US | disclosed |
| US-4985395-A | Dye-donor element for thermal dye sublimation transfer | AGFA-GEVAERT, N.V. (BE) | 1991-01-15 | — | — | US | disclosed |
| EP-0384040-A1 | Dye-donor element for thermal dye sublimation transfer | AGFA-GEVAERT N.V. (BE) | 1990-08-29 | — | — | EP | disclosed |
| JP-S649968-A | 1,3-BIS(DICYANOMETHYLENE)INDANE DERIVATIVE AND PRODUCTION THEREOF | SUMITOMO CHEMICAL CO | 1989-01-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023387-B2 | NIR-II emissive luminogens | DBI, UACA, BRI3BP | EGFR 2209/4885GAA 2375/4885ALDH1A1 1798/4885 |
| US-12622966-B2 | Compound for photothermal cancer therapy, composition including the same, and method for photothermal cancer therapy | BRCA1, TP53, MKI67 | EGFR 65/4885GAA 2130/4885ALDH1A1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.